Volume | 270,161 |
|
|||||
News | - | ||||||
Day High | 1.85 | Low High |
|||||
Day Low | 1.762 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Corvus Pharmaceuticals Inc | CRVS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.79 | 1.762 | 1.85 | 1.79 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
714 | 270,161 | $ 1.81 | $ 487,696 | - | 0.607 - 4.19 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:58:26 | 1 | $ 1.80 | USD |
Corvus Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
88.27M | 49.04M | - | 0 | -41.31M | -0.84 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Corvus Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRVS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.92 | 1.95 | 1.71 | 1.79 | 267,806 | -0.12 | -6.25% |
1 Month | 2.30 | 2.3899 | 1.71 | 1.98 | 234,615 | -0.50 | -21.74% |
3 Months | 1.92 | 2.58 | 1.71 | 2.11 | 217,581 | -0.12 | -6.25% |
6 Months | 1.47 | 2.58 | 1.05 | 1.80 | 208,981 | 0.33 | 22.45% |
1 Year | 0.6405 | 4.19 | 0.607 | 2.22 | 473,547 | 1.16 | 181.03% |
3 Years | 3.05 | 9.54 | 0.607 | 4.85 | 1,003,950 | -1.25 | -40.98% |
5 Years | 4.00 | 9.54 | 0.607 | 4.73 | 839,872 | -2.20 | -55.00% |
Corvus Pharmaceuticals Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant. |